Scientific deep-dive
What to Eat on a GLP-1: The Protein, Hydration, and Fiber Guide for Semaglutide and Tirzepatide
GLP-1 therapy reduces caloric intake automatically — but the remaining calories you eat still matter enormously. This guide walks through the evidence-based protein target for lean mass preservation, the fiber and hydration targets that reduce GI side effects, the foods that commonly trigger GI side effects, and how to actually eat during the slow-loss plateau phase.
- Nutrition
- Protein
- Patient guide
GLP-1 therapy reduces caloric intake automatically — appetite drops, meals get smaller, snacking mostly stops. The problem is that when patients eat less of everything, they also eat less of the things they specifically need to preserve lean mass and keep GI side effects tolerable: protein, fiber, and water. This guide walks through the evidence-based daily targets for protein, fiber, and hydration during GLP-1 therapy, the foods that consistently trigger nausea / reflux / constipation on a GLP-1, and what to actually eat during the slow-loss plateau phase. Sourced from the STEP trial protocols, the Wharton 2022 clinical practice review on GI side effect management [3], and the nutrition literature on protein intake during weight loss [4, 5].
The three daily targets that matter
The STEP-1 trial [1] included dietary counseling for every participant as part of the protocol — patients were not just told to take the drug and eat whatever. The counseling emphasized three specific targets that the nutrition literature supports independently of GLP-1 therapy [4, 5]:
| Target | Daily amount | Why |
|---|---|---|
| Protein | 1.2-1.6 g per kg of body weight | Preserve lean mass during weight loss |
| Fiber | 25-35 g | Prevent constipation; improve satiety |
| Water | 2-3 liters (68-100 oz) | Prevent dehydration-induced kidney injury (a documented label warning) and reduce constipation + fatigue |
Why protein matters more on a GLP-1 than off one
When the body is in a caloric deficit, it breaks down both fat and lean tissue for energy. The ratio depends on protein intake and physical activity. The nutrition literature is consistent that adequate protein intake (at least 1.2 g/kg, ideally 1.6 g/kg) during weight loss substantially reduces lean mass loss compared to lower protein intake at the same caloric deficit [4, 5]. This is independent of whether the caloric deficit comes from diet, exercise, or GLP-1 therapy.
The challenge is that GLP-1 therapy blunts appetite non-selectively — patients don't crave protein more than carbohydrates, they just want less of everything. This means protein intake tends to fall in proportion to total intake, and in practice many GLP-1 patients end up well below 1.0 g/kg of body weight in protein without realizing it. The consequence, documented in our semaglutide and muscle mass deep-dive, is that up to 40% of total weight lost on semaglutide can be lean mass in patients who don't prioritize protein and resistance training.
Practical protein targets for common body weights
| Starting body weight | Protein target (1.2 g/kg) | Protein target (1.6 g/kg) |
|---|---|---|
| 150 lb (68 kg) | 82 g | 109 g |
| 200 lb (91 kg) | 109 g | 146 g |
| 250 lb (113 kg) | 136 g | 181 g |
| 300 lb (136 kg) | 163 g | 218 g |
For most patients, the practical target is somewhere in the 1.2-1.4 g/kg range, which translates to roughly 100-150 g of protein per day for the typical adult. On a GLP-1, this is harder than it sounds because the appetite suppression is real — so the strategy becomes protein-first eating: eat the protein portion of every meal before the carbohydrates and vegetables.
Protein-dense foods that work on a GLP-1
- Greek yogurt (non-fat or 2%): 15-20 g protein per cup, easy to eat when appetite is low, generally well-tolerated on a GLP-1
- Cottage cheese: 25 g protein per cup, excellent protein density
- Eggs: 6 g protein per egg, small serving size is GLP-1-friendly
- Chicken breast: ~30 g per 100g serving; lean and easy to digest
- Fish (salmon, tuna, white fish): 20-25 g per serving, omega-3s are a bonus
- Whey or plant-based protein shakes: 20-30 g per serving, liquid format is often tolerated when solid food isn't
- Lean ground beef or turkey: 20-25 g per 100g serving
- Tofu and tempeh: 15-20 g per 100g serving, plant-based option
Fiber and hydration
The most common documented non-nausea GI complaint on GLP-1 therapy is constipation [3]. The mechanism is partly drug-specific (GLP-1s slow GI transit) and partly dietary — reduced total food intake means reduced fiber and water intake, which amplifies the constipation. The fix is direct:
- Fiber target: 25-35 g per day. Most patients on a GLP-1 end up well below this because the fiber-rich foods (whole grains, beans, vegetables) are filling and get displaced by more appealing options. Prioritize vegetables at every meal, add berries and high-fiber fruit, include beans or lentils where possible.
- Water target: 2-3 liters per day. Patients consistently under-drink on GLP-1s because thirst sensation is blunted along with appetite. Chronic mild dehydration manifests as fatigue (see our side effects duration guide) and increases constipation. Set a daily water target and track it; don't rely on thirst alone.
Foods that commonly trigger nausea on a GLP-1
The Wharton 2022 clinical practice review [3] documented the most common patient-reported nausea triggers. These aren't absolute rules — individuals vary — but the pattern is consistent:
- High-fat meals. The slowed gastric emptying effect of GLP-1s is amplified by fatty foods, which take longer to digest and tend to sit in the stomach. Fried foods, heavy cream sauces, and greasy fast food produce the worst post-meal nausea.
- Large portions. Eating past fullness consistently triggers nausea and vomiting. Most patients need to reduce portion sizes dramatically — meals that would have been normal before starting the drug are now too much.
- Sugary drinks and desserts. Rapid sugar intake can produce a dumping-syndrome-like response on a GLP-1 with nausea, sweating, and rapid heart rate. Patients often report becoming more “sugar- sensitive” on therapy.
- Alcohol. Alcohol amplifies GLP-1 nausea and can cause unexpected intoxication because of delayed gastric emptying. Many patients report they cannot tolerate the amount of alcohol they used to drink.
- Very spicy or very acidic foods. These can amplify the mild reflux that some patients develop on GLP-1 therapy.
- Carbonated drinks. Bloating and GI discomfort are more common on GLP-1 therapy, and carbonation amplifies both.
Foods that are consistently well-tolerated
- Lean protein sources listed above
- Plain rice, quinoa, oatmeal
- Bananas, apples, berries
- Cooked vegetables (softer than raw)
- Broth-based soups
- Plain crackers
- Room-temperature foods (hot food sometimes worsens nausea)
Meal timing and structure
The clinical practice guidance from Wharton 2022 [3] and patient-experience consensus converges on a few practical eating patterns that work better than others on GLP-1 therapy:
- Smaller, more frequent meals. Three very small meals plus 1-2 small snacks is usually better tolerated than two large meals.
- Stop eating when you feel full, not when the plate is empty. Full on a GLP-1 comes earlier than before and ignoring it triggers nausea within the hour. Re-train your stop signals.
- Protein first. Eat the protein portion of every meal first. If you fill up halfway through, at least you got the protein in.
- Eat slowly. GLP-1s delay the fullness signal from reaching the brain slightly, so fast eating produces overeating followed by nausea. Aim for 20-30 minutes per meal.
- Hydrate between meals, not during. Drinking large amounts of water with meals fills the already-slow-emptying stomach faster and triggers nausea. Drink water 30 minutes before or after meals instead.
What to eat during the slow-loss plateau
As covered in our plateau guide, the weight loss curve naturally flattens after week 40-52. During the plateau phase, body composition becomes more important than body weight — the goal is to lose fat, not muscle. The dietary adjustments for the plateau phase:
- Prioritize protein at the higher end of the range (1.4-1.6 g/kg) to preserve lean mass as you enter the slow phase.
- Add resistance training 2-3 times per week. The combination of adequate protein and resistance training is the only intervention in the literature that consistently preserves lean mass during weight loss [4, 5].
- Track waist circumference in addition to body weight — a flat scale with a shrinking waist is a good sign during the plateau phase.
- Don't increase the caloric deficit further. GLP-1s already produce a significant deficit and pushing it further typically just accelerates lean mass loss without producing more fat loss.
Alcohol and GLP-1s — a specific note
Many patients report dramatically reduced alcohol tolerance on GLP-1 therapy. This is consistent with the emerging literature on GLP-1 effects on the brain reward system (covered in our GLP-1 and alcohol use disorder deep-dive). Practical implications:
- Expect to drink significantly less than you used to — the same 2 drinks may feel like 4 on a GLP-1.
- Alcohol amplifies GLP-1 nausea, especially when combined with food.
- Alcohol calories still count — liquid calories are famously easy to under-track, and they can offset a meaningful portion of the caloric deficit the drug is producing.
Related research and tools
For the lean-mass preservation protocol with exact protein and resistance training targets, see our semaglutide and muscle mass deep-dive. For managing the GI side effects that eating patterns can amplify or reduce, see our side effects duration guide. For the plateau phase eating strategy, see our plateau guide. For the trial-curve timing that determines when each phase begins, see our onset guide. For the alcohol context, see our GLP-1 and alcohol deep-dive.
References
- 1.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
- 2.Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP-1 extension). Diabetes, Obesity and Metabolism. 2022. PMID: 35441470.
- 3.Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino DM, Pedersen SD. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine. 2022. PMID: 36177722.
- 4.Morton RW, Murphy KT, McKellar SR, Schoenfeld BJ, Henselmans M, Helms E, Aragon AA, Devries MC, Banfield L, Krieger JW, Phillips SM. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine. 2018. PMID: 28698222.
- 5.Cava E, Yeat NC, Mittendorfer B. Preserving Healthy Muscle during Weight Loss. Advances in Nutrition. 2017. PMID: 28507015.
- 6.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, patient counseling section. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf